Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)

Price$13.32

Value ScoreD

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-15.99%

Price vs S&P 500 (4W)-9.34%

VGM Score65.61

Market Capitalization$1.48B

All Metrics

Book Value / Share (Quarterly)$2.46

P/TBV (Annual)2.61x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)574.28%

Cash Flow / Share (Quarterly)$-1.09

Price vs S&P 500 (YTD)7.44%

Gross Margin (TTM)82.75%

Net Profit Margin (TTM)-94.56%

EPS (TTM)$-1.51

10-Day Avg Trading Volume1.02M

EPS Excl Extra (TTM)$-1.51

Revenue Growth (5Y)127.75%

EPS (Annual)$-1.53

ROI (Annual)-47.41%

Gross Margin (Annual)63.22%

Net Profit Margin (5Y Avg)-7716.48%

Cash / Share (Quarterly)$2.52

ROA (Last FY)-43.51%

EBITD / Share (TTM)$-1.58

ROE (5Y Avg)-75.43%

Operating Margin (TTM)-99.16%

Cash Flow / Share (Annual)$-1.12

P/B Ratio5.42x

P/B Ratio (Quarterly)5.62x

Net Income / Employee (Annual)$-1,064,200

EV / Revenue (TTM)6.34x

Net Interest Coverage (TTM)-10.93x

ROA (TTM)-50.73%

EV / EBITDA (TTM)31.38x

EPS Incl Extra (Annual)$-1.53

Current Ratio (Annual)14.27x

Quick Ratio (Quarterly)17.52x

3-Month Avg Trading Volume1.08M

52-Week Price Return190.85%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$6.20

P/S Ratio (Annual)16.95x

Asset Turnover (Annual)0.45x

52-Week High$18.61

Operating Margin (5Y Avg)-7253.97%

EPS Excl Extra (Annual)$-1.53

CapEx CAGR (5Y)-1.78%

26-Week Price Return-4.60%

Quick Ratio (Annual)13.98x

13-Week Price Return-4.92%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)17.85x

Enterprise Value$1.25B

Revenue / Share Growth (5Y)119.26%

Asset Turnover (TTM)0.50x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-345.81%

Cash / Share (Annual)$2.88

3-Month Return Std Dev56.19%

Net Income / Employee (TTM)$-1,103,800

ROE (Last FY)-47.41%

EPS Basic Excl Extra (Annual)$-1.53

Receivables Turnover (TTM)0.00x

EV / Free Cash Flow (TTM)410.90x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.51

Receivables Turnover (Annual)0.00x

ROI (TTM)-55.69%

P/S Ratio (TTM)7.54x

Pretax Margin (5Y Avg)-7715.61%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.12

Price vs S&P 500 (52W)163.81%

Year-to-Date Return18.46%

5-Day Price Return-0.28%

EPS Normalized (Annual)$-1.53

ROA (5Y Avg)-64.75%

Net Profit Margin (Annual)-345.36%

Month-to-Date Return-0.28%

Cash Flow / Share (TTM)$0.04

EBITD / Share (Annual)$-1.62

Operating Margin (Annual)-360.22%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-75.43%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.51

P/TBV (Quarterly)2.13x

P/B Ratio (Annual)4.35x

Inventory Turnover (TTM)1.68x

Pretax Margin (TTM)-93.56%

Book Value / Share (Annual)$2.78

Price vs S&P 500 (13W)-15.42%

Beta-0.14x

P/FCF (Annual)138.70x

Revenue / Share (TTM)$0.00

ROE (TTM)-55.69%

52-Week Low$4.76

vGradeD

gGradeA

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.37est. -0.34

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.38

4.33

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
AMLXAmylyx Pharmaceuticals, Inc. Common Stock	D	A	B	$13.32
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for amyotrophic lateral sclerosis, neurodegenerative diseases, and endocrine disorders. The company is focused on addressing unmet medical needs in these therapeutic areas.